Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVE-Treg
- Development stage
- Phase 1
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Regulatory T Cells (Tregs) → Immune Effector Cells → Other Cell Types → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Subcutaneous (for Concomitant IL-2)
01
Overview
EVE-Treg refers to **ex vivo-expanded regulatory T cells** (Tregs) used as a cell therapy to suppress aberrant immune responses in conditions such as chronic graft-versus-host disease (cGVHD). The approach involves isolating regulatory T cells from the patient or donor, expanding them outside the body (ex vivo), and then infusing them back into the patient to restore immune tolerance and control inflammation. EVE-Treg is being studied in clinical trials in combination with low-dose interleukin-2 (IL-2), which supports Treg survival and function. The primary indication is for patients with steroid-refractory cGVHD, though Treg therapies are broadly investigated for autoimmune diseases and organ transplantation[4][6].
- Brand names
- EVE-Treg
- Other names
- EVE-Treg
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on EVE-Treg.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EVE-Treg.